Cargando…

Hepatocellular carcinoma: Can LI-RADS v2017 with gadoxetic-acid enhancement magnetic resonance and diffusion-weighted imaging improve diagnostic accuracy?

BACKGROUND: The Liver Imaging Reporting and Data System (LI-RADS), supported by the American College of Radiology (ACR), has been developed for standardizing the acquisition, interpretation, reporting, and data collection of liver imaging examinations in patients at risk for hepatocellular carcinoma...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Tong, Huang, Zi-Xing, Wei, Yi, Jiang, Han-Yu, Chen, Jie, Liu, Xi-Jiao, Cao, Li-Kun, Duan, Ting, He, Xiao-Peng, Xia, Chun-Chao, Song, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371008/
https://www.ncbi.nlm.nih.gov/pubmed/30774276
http://dx.doi.org/10.3748/wjg.v25.i5.622
_version_ 1783394475099291648
author Zhang, Tong
Huang, Zi-Xing
Wei, Yi
Jiang, Han-Yu
Chen, Jie
Liu, Xi-Jiao
Cao, Li-Kun
Duan, Ting
He, Xiao-Peng
Xia, Chun-Chao
Song, Bin
author_facet Zhang, Tong
Huang, Zi-Xing
Wei, Yi
Jiang, Han-Yu
Chen, Jie
Liu, Xi-Jiao
Cao, Li-Kun
Duan, Ting
He, Xiao-Peng
Xia, Chun-Chao
Song, Bin
author_sort Zhang, Tong
collection PubMed
description BACKGROUND: The Liver Imaging Reporting and Data System (LI-RADS), supported by the American College of Radiology (ACR), has been developed for standardizing the acquisition, interpretation, reporting, and data collection of liver imaging examinations in patients at risk for hepatocellular carcinoma (HCC). Diffusion-weighted imaging (DWI), which is described as an ancillary imaging feature of LI-RADS, can improve the diagnostic efficiency of LI-RADS v2017 with gadoxetic acid-enhanced magnetic resonance imaging (MRI) for HCC. AIM: To determine whether the use of DWI can improve the diagnostic efficiency of LI-RADS v2017 with gadoxetic acid-enhanced magnetic resonance MRI for HCC. METHODS: In this institutional review board-approved study, 245 observations of high risk of HCC were retrospectively acquired from 203 patients who underwent gadoxetic acid-enhanced MRI from October 2013 to April 2018. Two readers independently measured the maximum diameter and recorded the presence of each lesion and assigned scores according to LI-RADS v2017. The test was used to determine the agreement between the two readers with or without DWI. In addition, the sensitivity (SE), specificity (SP), accuracy (AC), positive predictive value (PPV), and negative predictive value (NPV) of LI-RADS were calculated. Youden index values were used to compare the diagnostic performance of LI-RADS with or without DWI. RESULTS: Almost perfect interobserver agreement was obtained for the categorization of observations with LI-RADS (kappa value: 0.813 without DWI and 0.882 with DWI). For LR-5, the diagnostic SE, SP, and AC values were 61.2%, 92.5%, and 71.4%, respectively, with or without DWI; for LR-4/5, they were 73.9%, 80%, and 75.9% without DWI and 87.9%, 80%, and 85.3% with DWI; for LR-4/5/M, they were 75.8%, 58.8%, and 70.2% without DWI and 87.9%, 58.8%, and 78.4% with DWI; for LR- 4/5/TIV, they were 75.8%, 75%, and 75.5% without DWI and 89.7%, 75%, and 84.9% with DWI. The Youden index values of the LI-RADS classification without or with DWI were as follows: LR-4/5: 0.539 vs 0.679; LR-4/5/M: 0.346 vs 0.467; and LR-4/5/TIV: 0.508 vs 0.647. CONCLUSION: LI-RADS v2017 has been successfully applied with gadoxetate-enhanced MRI for patients at high risk for HCC. The addition of DWI significantly increases the diagnostic efficiency for HCC.
format Online
Article
Text
id pubmed-6371008
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-63710082019-02-15 Hepatocellular carcinoma: Can LI-RADS v2017 with gadoxetic-acid enhancement magnetic resonance and diffusion-weighted imaging improve diagnostic accuracy? Zhang, Tong Huang, Zi-Xing Wei, Yi Jiang, Han-Yu Chen, Jie Liu, Xi-Jiao Cao, Li-Kun Duan, Ting He, Xiao-Peng Xia, Chun-Chao Song, Bin World J Gastroenterol Retrospective Study BACKGROUND: The Liver Imaging Reporting and Data System (LI-RADS), supported by the American College of Radiology (ACR), has been developed for standardizing the acquisition, interpretation, reporting, and data collection of liver imaging examinations in patients at risk for hepatocellular carcinoma (HCC). Diffusion-weighted imaging (DWI), which is described as an ancillary imaging feature of LI-RADS, can improve the diagnostic efficiency of LI-RADS v2017 with gadoxetic acid-enhanced magnetic resonance imaging (MRI) for HCC. AIM: To determine whether the use of DWI can improve the diagnostic efficiency of LI-RADS v2017 with gadoxetic acid-enhanced magnetic resonance MRI for HCC. METHODS: In this institutional review board-approved study, 245 observations of high risk of HCC were retrospectively acquired from 203 patients who underwent gadoxetic acid-enhanced MRI from October 2013 to April 2018. Two readers independently measured the maximum diameter and recorded the presence of each lesion and assigned scores according to LI-RADS v2017. The test was used to determine the agreement between the two readers with or without DWI. In addition, the sensitivity (SE), specificity (SP), accuracy (AC), positive predictive value (PPV), and negative predictive value (NPV) of LI-RADS were calculated. Youden index values were used to compare the diagnostic performance of LI-RADS with or without DWI. RESULTS: Almost perfect interobserver agreement was obtained for the categorization of observations with LI-RADS (kappa value: 0.813 without DWI and 0.882 with DWI). For LR-5, the diagnostic SE, SP, and AC values were 61.2%, 92.5%, and 71.4%, respectively, with or without DWI; for LR-4/5, they were 73.9%, 80%, and 75.9% without DWI and 87.9%, 80%, and 85.3% with DWI; for LR-4/5/M, they were 75.8%, 58.8%, and 70.2% without DWI and 87.9%, 58.8%, and 78.4% with DWI; for LR- 4/5/TIV, they were 75.8%, 75%, and 75.5% without DWI and 89.7%, 75%, and 84.9% with DWI. The Youden index values of the LI-RADS classification without or with DWI were as follows: LR-4/5: 0.539 vs 0.679; LR-4/5/M: 0.346 vs 0.467; and LR-4/5/TIV: 0.508 vs 0.647. CONCLUSION: LI-RADS v2017 has been successfully applied with gadoxetate-enhanced MRI for patients at high risk for HCC. The addition of DWI significantly increases the diagnostic efficiency for HCC. Baishideng Publishing Group Inc 2019-02-07 2019-02-07 /pmc/articles/PMC6371008/ /pubmed/30774276 http://dx.doi.org/10.3748/wjg.v25.i5.622 Text en ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Retrospective Study
Zhang, Tong
Huang, Zi-Xing
Wei, Yi
Jiang, Han-Yu
Chen, Jie
Liu, Xi-Jiao
Cao, Li-Kun
Duan, Ting
He, Xiao-Peng
Xia, Chun-Chao
Song, Bin
Hepatocellular carcinoma: Can LI-RADS v2017 with gadoxetic-acid enhancement magnetic resonance and diffusion-weighted imaging improve diagnostic accuracy?
title Hepatocellular carcinoma: Can LI-RADS v2017 with gadoxetic-acid enhancement magnetic resonance and diffusion-weighted imaging improve diagnostic accuracy?
title_full Hepatocellular carcinoma: Can LI-RADS v2017 with gadoxetic-acid enhancement magnetic resonance and diffusion-weighted imaging improve diagnostic accuracy?
title_fullStr Hepatocellular carcinoma: Can LI-RADS v2017 with gadoxetic-acid enhancement magnetic resonance and diffusion-weighted imaging improve diagnostic accuracy?
title_full_unstemmed Hepatocellular carcinoma: Can LI-RADS v2017 with gadoxetic-acid enhancement magnetic resonance and diffusion-weighted imaging improve diagnostic accuracy?
title_short Hepatocellular carcinoma: Can LI-RADS v2017 with gadoxetic-acid enhancement magnetic resonance and diffusion-weighted imaging improve diagnostic accuracy?
title_sort hepatocellular carcinoma: can li-rads v2017 with gadoxetic-acid enhancement magnetic resonance and diffusion-weighted imaging improve diagnostic accuracy?
topic Retrospective Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371008/
https://www.ncbi.nlm.nih.gov/pubmed/30774276
http://dx.doi.org/10.3748/wjg.v25.i5.622
work_keys_str_mv AT zhangtong hepatocellularcarcinomacanliradsv2017withgadoxeticacidenhancementmagneticresonanceanddiffusionweightedimagingimprovediagnosticaccuracy
AT huangzixing hepatocellularcarcinomacanliradsv2017withgadoxeticacidenhancementmagneticresonanceanddiffusionweightedimagingimprovediagnosticaccuracy
AT weiyi hepatocellularcarcinomacanliradsv2017withgadoxeticacidenhancementmagneticresonanceanddiffusionweightedimagingimprovediagnosticaccuracy
AT jianghanyu hepatocellularcarcinomacanliradsv2017withgadoxeticacidenhancementmagneticresonanceanddiffusionweightedimagingimprovediagnosticaccuracy
AT chenjie hepatocellularcarcinomacanliradsv2017withgadoxeticacidenhancementmagneticresonanceanddiffusionweightedimagingimprovediagnosticaccuracy
AT liuxijiao hepatocellularcarcinomacanliradsv2017withgadoxeticacidenhancementmagneticresonanceanddiffusionweightedimagingimprovediagnosticaccuracy
AT caolikun hepatocellularcarcinomacanliradsv2017withgadoxeticacidenhancementmagneticresonanceanddiffusionweightedimagingimprovediagnosticaccuracy
AT duanting hepatocellularcarcinomacanliradsv2017withgadoxeticacidenhancementmagneticresonanceanddiffusionweightedimagingimprovediagnosticaccuracy
AT hexiaopeng hepatocellularcarcinomacanliradsv2017withgadoxeticacidenhancementmagneticresonanceanddiffusionweightedimagingimprovediagnosticaccuracy
AT xiachunchao hepatocellularcarcinomacanliradsv2017withgadoxeticacidenhancementmagneticresonanceanddiffusionweightedimagingimprovediagnosticaccuracy
AT songbin hepatocellularcarcinomacanliradsv2017withgadoxeticacidenhancementmagneticresonanceanddiffusionweightedimagingimprovediagnosticaccuracy